Verified Insights
Precision-driven research you can trust. We uphold rigorous data validation processes to ensure every report is reliable and based on credible sources.
+91 9425150513 (Asia) support@24lifesciences.com
+91 9425150513 (Asia) support@24lifesciences.com
MARKET INSIGHTS
The global pleural biopsy market was valued at USD 1.2 billion in 2024 and is projected to reach USD 1.8 billion by 2031, growing at a CAGR of 5.7% during the forecast period. This growth is primarily driven by increasing prevalence of respiratory diseases, rising demand for minimally invasive diagnostic procedures, and technological advancements in biopsy techniques.
Pleural biopsy is a critical diagnostic procedure used to obtain tissue samples from the pleura the thin membrane surrounding the lungs for pathological examination. It plays a vital role in evaluating conditions such as tuberculosis, pleural effusions, and particularly malignant diseases including mesothelioma and metastatic cancers. The procedure can be performed through various methods including image-guided needle biopsy, thoracoscopic biopsy, and open surgical biopsy, with increasing preference for minimally invasive techniques.
While North America currently dominates the market due to advanced healthcare infrastructure and high mesothelioma incidence rates, the Asia-Pacific region is expected to witness the fastest growth owing to improving healthcare access and rising disease awareness. Key market players such as Olympus, Boston Scientific, and Medtronic are focusing on developing advanced biopsy devices with improved accuracy and safety profiles, further propelling market expansion.
Rising Prevalence of Pleural Diseases
The increasing incidence of lung cancer, mesothelioma, and pleural infections is driving demand for pleural biopsy procedures. Approximately 1.8 million new lung cancer cases are diagnosed globally each year, often requiring diagnostic pleural biopsies.
Technological Advancements in Biopsy Techniques
Innovations such as image-guided pleural biopsy and medical thoracoscopy have improved diagnostic accuracy to over 90%, reducing the need for more invasive surgical procedures and driving market growth.
Image-guided techniques now account for over 65% of all pleural biopsies performed in developed markets
The development of safer, minimally invasive techniques with lower complication rates continues to expand the eligible patient population for pleural biopsy procedures.
MARKET CHALLENGES
Procedure-Related Risks and Complications
Pleural biopsy procedures carry inherent risks including pneumothorax (reported in 5-15% of cases), bleeding, and infection, which pose challenges to market expansion.
Other Challenges
Lack of Skilled Professionals
The procedure requires specialized training, and many healthcare facilities in developing regions lack adequately trained pulmonologists or interventional radiologists.
High Costs of Advanced Equipment
Medical thoracoscopy systems and imaging guidance equipment represent significant capital investments, limiting adoption in resource-constrained settings.
Alternative Diagnostic Methods
The availability of liquid biopsy and molecular testing for some malignancies reduces the necessity for invasive pleural tissue sampling, particularly in advanced cancer cases where treatment decisions may rely more on genomic profiling.
Emerging Markets Expansion
Developing regions with improving healthcare infrastructure represent significant growth opportunities, particularly as diagnostic capabilities for tuberculosis and occupational lung diseases expand in these markets.
Integration with Molecular Diagnostics
The combination of traditional biopsy with rapid molecular testing creates new value propositions, enabling both histological assessment and targeted therapy selection from a single procedure.
Segment Analysis:| Segment Category | Sub-Segments | Key Insights |
| By Type |
|
Malignancy biopsies represent the most critical segment due to the rising incidence of malignant mesothelioma and lung cancers. The procedure's ability to provide definitive tissue diagnosis makes it indispensable in oncology practice. Granulomatous biopsies are gaining importance in tuberculosis-endemic regions while lupus biopsies remain a niche application requiring specialized expertise. |
| By Application |
|
Hospitals maintain leadership as the primary setting for pleural biopsies due to their comprehensive diagnostic infrastructure and immediate access to thoracic surgery teams. Diagnostic laboratories are experiencing growth with the expansion of specialized pathology services, while cancer research institutes contribute significantly to procedural innovation and technique refinement. |
| By End User |
|
Pulmonologists remain the principal users of pleural biopsy techniques, leveraging their expertise in respiratory medicine. Thoracic surgeons are increasingly adopting advanced biopsy methods during surgical interventions, while interventional radiologists are driving demand for image-guided procedures that offer greater precision and patient comfort. |
| By Procedure Technique |
|
Thoracoscopic biopsy is emerging as the gold standard technique, providing superior visualization and sample quality while minimizing patient discomfort. Needle biopsies continue to be widely used for initial diagnostic workups, whereas open surgical biopsies are reserved for complex cases requiring extensive tissue sampling. |
| By Disease Indication |
|
Malignant pleural effusion dominates as the primary clinical indication for pleural biopsies, driven by increasing cancer prevalence. Tuberculous pleuritis maintains significance in high-burden countries, while idiopathic pleuritis creates diagnostic challenges that require comprehensive tissue analysis, supporting continued biopsy demand despite advances in fluid analysis techniques. |
Innovative Medical Device Leaders Driving Pleural Biopsy Market Growth
The pleural biopsy market is dominated by global medical technology leaders like Olympus and Boston Scientific, which collectively hold significant market share through their advanced biopsy devices and global distribution networks. These companies benefit from extensive R&D capabilities and strategic partnerships with healthcare institutions. The market exhibits moderate consolidation with top 5 players accounting for approximately 45% of total revenue in 2024, while smaller specialized manufacturers focus on niche applications.
Several emerging players are gaining traction through technological innovations in minimally invasive biopsy systems. Companies like KARL STORZ and Fujifilm are focusing on high-resolution imaging integration with biopsy devices, while specialty manufacturers such as B. Braun Melsungen emphasize safety and precision in pleural tissue sampling. Regional players are also expanding their presence, particularly in Asia-Pacific markets with growing healthcare infrastructure.
List of Key Pleural Biopsy Companies ProfiledOlympus Corporation
B. Braun Melsungen AG
Medtronic plc
Fujifilm Holdings Corporation
Cardinal Health, Inc.
Hologic, Inc.
CONMED Corporation
Argon Medical Devices, Inc.
Merit Medical Systems, Inc.
R. Bard, Inc. (BD)
The global pleural biopsy market is projected to grow from $85 million in 2024 to $127 million by 2031, at a CAGR of 5.8%. This growth is primarily fueled by increasing cases of lung cancer, mesothelioma, and tuberculosis worldwide. North America currently leads with 38% market share, followed by Europe (27%) and Asia-Pacific (22%). The expanding elderly population vulnerable to pleural diseases further accelerates market expansion.
Other TrendsTechnological Advancements in Biopsy Devices
Key players like Olympus and Medtronic are investing heavily in developing minimally invasive biopsy equipment with enhanced imaging capabilities. The adoption of CT-guided and ultrasound-assisted pleural biopsy procedures has increased diagnostic accuracy to 92-95%. Emerging robotic-assisted systems are expected to revolutionize the market by 2026.
Growing Preference for Hospital-Based ProceduresHospitals accounted for 64% of pleural biopsy procedures in 2023 due to better infrastructure for complication management. However, cancer research institutes are witnessing the fastest growth (11.3% CAGR) owing to increased mesothelioma research funding. The diagnostics laboratories segment is expanding through partnerships with imaging centers.
Market Consolidation Through Strategic Acquisitions
Major industry developments include Boston Scientific's acquisition of a thoracic diagnostics firm and Fujifilm's partnership with leading cancer centers. The top 5 companies collectively hold 58% market share, with Olympus maintaining the lead position at 19% revenue share. Regional players are gaining traction in Asia through cost-effective solutions.
Regulatory Focus on Patient Safety StandardsStringent FDA and EU regulations on biopsy device approvals are shaping product development strategies. Manufacturers are prioritizing single-use disposable kits to prevent cross-contamination, which now represent 43% of the product mix. Compliance with ISO 13485 standards has become a key differentiator in procurement decisions.
Regional Analysis: Pleural Biopsy MarketEurope
Europe maintains significant pleural biopsy market share with harmonized medical device regulations across EU countries. Germany and France lead in adoption of medical thoracoscopy procedures. The region shows growing preference for minimally invasive techniques amid rising awareness of early diagnosis benefits. National healthcare systems increasingly incorporate pleural biopsy in diagnostic protocols for respiratory diseases. Eastern European markets demonstrate slower adoption rates due to budget constraints, though improving healthcare infrastructure shows promise for future growth.
Asia-Pacific
Asia-Pacific emerges as the fastest-growing pleural biopsy market, driven by expanding healthcare access and rising disease burden. Japan leads with technologically advanced hospitals implementing robotic-assisted biopsies. China and India show rapid market expansion through local manufacturing and increasing thoracic surgery volumes. Challenges remain in rural healthcare penetration and cost containment. Regional players focus on developing affordable biopsy solutions while multinationals establish specialty training centers to build procedural expertise.
South America
South America experiences steady pleural biopsy market growth, with Brazil and Argentina as key markets. Urban healthcare centers increasingly adopt thoracoscopic techniques, while rural areas rely on basic needle biopsies. Economic volatility impacts high-end device adoption, though government healthcare programs gradually improve diagnostic access. Local manufacturers gain market share with cost-effective solutions tailored to regional healthcare budgets.
Middle East & Africa
The Middle East shows promising pleural biopsy market growth, particularly in Gulf countries with advanced medical infrastructure. South Africa leads the African market through private healthcare investments. Across the region, market expansion faces challenges from limited specialist availability and procedural training gaps. International collaborations aim to build local diagnostic capabilities, with growing adoption of telemedicine for expert consultations on complex cases.
This market research report offers a holistic overview of global and regional markets for the forecast period 20252032. It presents accurate and actionable insights based on a blend of primary and secondary research.
Market Overview
Global and regional market size (historical & forecast)
Growth trends and value/volume projections
Segmentation Analysis
By product type or category
By application or usage area
By end-user industry
By distribution channel (if applicable)
Regional Insights
North America, Europe, Asia-Pacific, Latin America, Middle East & Africa
Country-level data for key markets
Competitive Landscape
Company profiles and market share analysis
Key strategies: M&A, partnerships, expansions
Product portfolio and pricing strategies
Technology & Innovation
Emerging technologies and R&D trends
Automation, digitalization, sustainability initiatives
Impact of AI, IoT, or other disruptors (where applicable)
Market Dynamics
Key drivers supporting market growth
Restraints and potential risk factors
Supply chain trends and challenges
Opportunities & Recommendations
High-growth segments
Investment hotspots
Strategic suggestions for stakeholders
Stakeholder Insights
This report is designed to support strategic decision-making for a wide range of stakeholders, including:
Medical device manufacturers
Diagnostic equipment suppliers
Healthcare providers and hospital networks
Biotech and pharmaceutical companies
Investors and research institutions
-> Global pleural biopsy market was valued at USD 1.2 billion in 2024 and is projected to reach USD 1.8 billion by 2031.
-> Key players include Olympus, Boston Scientific, B. Braun Melsungen, KARL STORZ, and Medtronic.
-> Key growth drivers include increasing prevalence of respiratory diseases and rising demand for minimally invasive diagnostic procedures.
-> North America currently dominates the market, while Asia-Pacific is expected to witness fastest growth.
-> Emerging trends include development of advanced biopsy devices with improved accuracy and safety profiles.
“The data provided by 24LifeScience was clear, well-organized, and useful for internal strategy planning. It helped us understand the competitive landscape more effectively.”
“We used one of their market overview reports for early-stage feasibility work. It gave us a helpful snapshot of current trends and key players in our therapeutic area.”
“I appreciated the team’s responsiveness and willingness to adjust the scope based on our feedback. The final report was aligned with our expectations and timelines.”
“Their custom report on clinical trial trends was a helpful reference as we explored new indications."
“As someone working on early product planning, I found their therapeutic area briefs quite useful. The information was presented in a way that made it easy to extract key takeaways.”
“We didn’t need anything overly complex—just solid, dependable data. 24LifeScience delivered exactly that, without unnecessary fluff.”
“Their reports gave us a good foundation to start our own market assessment. While we supplemented it with other data, this was a great starting point.”
“I’ve used a few of their reports for academic and grant writing purposes. They’re generally well-cited and reliable for understanding market scope.”
At 24LifeScience, we combine domain expertise with dependable research delivery. What truly differentiates us isn't just what we do — it's how we do it. Our clients trust us because we offer consistency, security, value, and most importantly, insight that drives action.
Precision-driven research you can trust. We uphold rigorous data validation processes to ensure every report is reliable and based on credible sources.
We uphold rigorous data validation processes to ensure every report is reliable, up-to-date, and based on credible sources.
24LifeScience powers research for top firms in 20+ nations.Chosen by leading life sciences companies worldwide.
We offer competitive pricing models that align with your project scope — no hidden charges, no lock-in. Tailored pricing for every scale and need.
8–10+ years of life sciences expertise turned into strategic insights.We don’t just summarize data we contextualize it.
Whether it's a ready-made report or a custom project, we deliver within the promised timeline With real-time updates